Cristal Therapeutics signs non-exclusive license of CliCr® bioconjugation platform with Sapreme Technologies
Maastricht, The Netherlands – 11 September 2025
Cristal Therapeutics, a biotech company developing innovative conjugation technologies, today announced it has entered into a non-exclusive license agreement with Sapreme Technologies. The agreement allows Sapreme Technologies to leverage the versatile and highly efficient CliCr® platform in the development of next-generation therapeutics based on their endosomal escape technology.
The CliCr® bioconjugation platform offers a powerful and scalable solution for efficient, site-specific and stable conjugation of biomolecules. Under the terms of the agreement, Cristal Therapeutics grants Sapreme Technologies a non-exclusive license to apply CliCr® across their research and development programs.
Dr. Marco Timmers, CEO of Sapreme Technologies, stated:
“Integrating CliCr® into Sapreme’s therapeutics based on our endosomal escape technology, allows us to accelerate our pipeline with a robust manufacturing strategy. We value Cristal Therapeutics’ deep expertise in the field and look forward to exploring the full potential of this innovative bioconjugation technology.”
Dr. Werner Cautreels, CEO of Cristal Therapeutics, commented:
“We are pleased to collaborate with Sapreme Technologies, a promising biotech with a strong commitment to next-generation therapeutics. This license deal is a validation of the growing interest in our CliCr® platform, which continues to demonstrate broad applicability and robust performance in drug development.”
The financial terms of the agreement were not disclosed.
